LIANY on OTC

LianBio

Pharmaceutical preparations company in the Cayman Islands. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

TickerLIANY on OTC¹
IndustryPharmaceutical Preparations¹
HeadquartersPrinceton, New Jersey¹
Incorporated inCayman Islands²
Business address103 Carnegie Center Drive, Suite 309, Princeton, Nj 08540²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴-$125.4M in 2022−7% since 2020

Net income³⁴-$110.3M in 2022−21% since 2020

Fiscal year	2020	2021	2022
Research and development	$120.9M³	$158.7M⁴	$59.8M⁴
Operating expenses		$195.6M⁴	$125.4M⁴
Operating income	-$134.9M³	-$195.6M⁴	-$125.4M⁴
Income before tax		-$195.8M⁴	-$110.6M⁴
Income tax	$4.0K³	$518.0K⁴	-$333.0K⁴
Net income	-$139.6M³	-$196.3M⁴	-$110.3M⁴
Earnings per share	-$11.58³	-$5.71⁴	-$1.02⁴
Earnings per share (diluted)	-$11.58³	-$5.71⁴	-$1.02⁴
Shares (weighted, basic)		34.4M shares⁴	107.9M shares⁴
Shares (weighted, diluted)		34.4M shares⁴	107.9M shares⁴

Total assets³⁴$320.0M in 2022+15% since 2020

Total liabilities³⁴$26.3M in 2022−5% since 2020

Shareholders’ equity³⁴$259.9M in 2022

Cash³⁴$79.2M in 2022+83% since 2019

Fiscal year	2019	2020	2021	2022	2023
Cash	$43.3M³	$254.3M³	$228.2M⁴	$79.2M⁴
Current assets		$276.7M³	$399.6M⁴	$312.8M⁴
Property, plant and equipment			$1.9M⁴	$3.1M⁴
Total assets		$279.3M³	$426.3M⁴	$320.0M⁴
Accounts payable			$3.2M⁴	$1.5M⁴
Current liabilities		$6.2M³	$15.1M⁴	$23.6M⁴
Total liabilities		$27.6M³	$39.0M⁴	$26.3M⁴
Retained earnings			-$360.2M⁴	-$470.5M⁴
Shareholders’ equity	-$14.8M³	-$132.8M³	$353.6M⁴	$259.9M⁴
Shares outstanding		20.5M shares³	107.3M shares⁴	107.0M shares⁴	107.2M shares⁴

Cash from operations³⁴-$99.2M in 2022+1% since 2020

Capital spending³⁴$1.8M in 2022+108% since 2020

Free cash flow³⁴-$101.0M in 2022+2% since 2020

Fiscal year	2020	2021	2022
Cash from operations	-$98.1M³	-$164.0M⁴	-$99.2M⁴
Stock-based compensation		$8.7M⁴	$19.1M⁴
Capital spending	$886.0K³	$947.0K⁴	$1.8M⁴
Free cash flow	-$99.0M	-$164.9M	-$101.0M
Cash from investing		-$155.9M⁴	-$69.2M⁴
Cash from financing		$313.3M⁴	$1.7M⁴

Compare LianBio with another company

Leadership

Who has led LianBio, and when. Pick a name to see everywhere that person has worked.

Chief executive

Chief financial officer

2025

Chief executive officerAdam Leo Stone Feb 20, 2024 to Feb 20, 2024⁷
Chief executive officerYizhe Wang Oct 29, 2021 to Mar 31, 2023⁸
Chief financial officerEhong Gu Dec 26, 2023 to Apr 11, 2024⁹
Chief financial officerYi Larson Oct 29, 2021 to Mar 31, 2023¹⁰

Board members and other officers (10)

Chief Business OfficerBrianne Jahn Oct 29, 2021 to Mar 31, 2023¹¹
OfficerDebra Yu Oct 29, 2021 to May 6, 2022¹²
Board memberAdam Leo Stone Oct 29, 2021 to Feb 20, 2024¹³
Board memberAnastasios Gianakakos Oct 29, 2021 to Feb 20, 2024¹⁴
Board memberJesse Wu Oct 29, 2021 to Nov 1, 2021¹⁵
Board memberKonstantin Poukalov Oct 29, 2021 to Feb 20, 2024¹⁶
Board memberNeil Kumar Oct 29, 2021 to Nov 9, 2021¹⁷
Board memberSusan Michele Silbermann Oct 29, 2021 to Feb 20, 2024¹⁸
Board memberYizhe Wang Oct 29, 2021 to Mar 31, 2023⁸
Board memberJoseph Edelman Nov 5, 2021 to Feb 20, 2024¹⁹

Timeline

Feb 20, 2024New chief executive Adam Leo Stone becomes CEO⁷
Oct 29, 2021New chief executive Yizhe Wang becomes CEO⁸

Filings

154 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 29 major events, 57 insider forms, 9 large holders, 49 other. The latest 20:

Nov 14, 2024SC 13G EDGAR
Apr 11, 20244 EDGAR
Mar 21, 202415-12G EDGAR
Mar 12, 2024EFFECT EDGAR
Mar 12, 2024S-8 POS EDGAR
Mar 12, 2024S-8 POS EDGAR
Mar 12, 2024S-8 POS EDGAR
Mar 12, 2024POS AM EDGAR
Mar 11, 202425 EDGAR
Feb 29, 2024SC 13D/A EDGAR
Feb 20, 20244 EDGAR
Feb 20, 20244 EDGAR
Feb 20, 20244 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
Feb 20, 20244 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
Feb 20, 20244 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
Feb 13, 20248-K EDGAR
Jan 8, 2024144 EDGAR
Dec 29, 2023144 EDGAR
Dec 26, 20233 EDGAR
Dec 26, 20238-K EDGAR

The 154 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 8 buys and 2 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Jan 2, 2024	Gu EhongInterim CFO	Sale	1,731	$4.34	$7.5K	Form 4
Jan 3, 2023	QIAN JIANGSVP, China General Manager	Sale	2,239	$1.65	$3.7K	Form 4
Aug 18, 2022	LEV LB Holdings GP, LLCDirector	Buy	998,240	$2.40	$2.4M	Form 4
May 26, 2022	LEV LB Holdings, LPDirector	Buy	69,000	$3.13	$216.0K	Form 4
May 25, 2022	Perceptive Venture Advisors, LLCDirector	Buy	120,000	$2.63	$315.6K	Form 4
May 24, 2022	Perceptive Venture Advisors, LLCDirector	Buy	42,551	$2.47	$105.1K	Form 4
May 23, 2022	Perceptive Venture Advisors, LLCDirector	Buy	8,700	$2.49	$21.7K	Form 4
Nov 3, 2021	LEV LB Holdings, LPDirector	Buy	2,270,000	$15.98	$36.3M	Form 4
Nov 2, 2021	Perceptive Venture Advisors, LLCDirector	Buy	100,000	$13.50	$1.4M	Form 4
Nov 1, 2021	Perceptive Venture Advisors, LLCDirector	Buy	120,000	$15.50	$1.9M	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

TANG CAPITAL MANAGEMENT LLCSC 13G, 1 filing Nov 14, 2024²⁰
PERCEPTIVE ADVISORS LLCSC 13D/A, 2 filings Nov 15, 2021 to Feb 29, 2024²¹
TANG CAPITAL PARTNERS LPSC 13D, 2 filings Nov 1, 2023 to Nov 30, 2023²²
Venrock Healthcare Capital Partners II, L.P.SC 13G/A, 2 filings Nov 10, 2021 to Feb 14, 2023²³
RA CAPITAL MANAGEMENT, L.P.SC 13G/A, 2 filings Nov 15, 2021 to Nov 14, 2022²⁴

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARLianBio filings on SEC EDGAR
2
SEC EDGARLianBio filings on SEC EDGAR
3
SEC EDGARLianBio 10-K for fiscal 2020
4
SEC EDGARLianBio 10-K for fiscal 2021
5
SEC EDGARLianBio 10-Q for fiscal 2023
6
SEC EDGARLianBio 10-Q for fiscal 2023
7
SEC EDGARAdam Leo Stone, Chief executive officer
8
SEC EDGARYizhe Wang, Chief executive officer
9
SEC EDGAREhong Gu, Chief financial officer
10
SEC EDGARYi Larson, Chief financial officer
11
SEC EDGARBrianne Jahn, Chief Business Officer
12
SEC EDGARDebra Yu, Officer
13
SEC EDGARAdam Leo Stone, Board member
14
SEC EDGARAnastasios Gianakakos, Board member
15
SEC EDGARJesse Wu, Board member
16
SEC EDGARKonstantin Poukalov, Board member
17
SEC EDGARNeil Kumar, Board member
18
SEC EDGARSusan Michele Silbermann, Board member
19
SEC EDGARJoseph Edelman, Board member
20
SEC EDGARTANG CAPITAL MANAGEMENT LLC SC 13G on LianBio
21
SEC EDGARPERCEPTIVE ADVISORS LLC SC 13D/A on LianBio
22
SEC EDGARTANG CAPITAL PARTNERS LP SC 13D on LianBio
23
SEC EDGARVenrock Healthcare Capital Partners II, L.P. SC 13G/A on LianBio
24
SEC EDGARRA CAPITAL MANAGEMENT, L.P. SC 13G/A on LianBio